MedTrace Logo

Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women

NCT02858037 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1456

Last updated 2022-10-25

Study results available
· View outcomes & findings →

Summary

HIV Open-label Prevention Extension (HOPE).

Conditions

  • Human Immunodeficiency Virus

Interventions

COMBINATION_PRODUCT

Dapivirine Vaginal Ring

Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.

Sponsors & Collaborators

  • International Partnership for Microbicides, Inc.

    lead INDUSTRY

Principal Investigators

  • John Steytler · International Partnership for Microbicides

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-18
Primary Completion
2018-10-10
Completion
2018-10-10
FDA Drug
Yes

Countries

  • Malawi
  • South Africa
  • Uganda
  • Zimbabwe

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02858037 on ClinicalTrials.gov